osteonecrosis of the jaw in patients taking bisphosphonates for osteoporosis

March 2009

You'll hear more controversy about osteonecrosis of the jaw in patients taking bisphosphonates for osteoporosis.

This destruction of the jaw bone was initially seen in patients on high doses of IV bisphosphonates for cancer.

The incidence with ORAL bisphosphonates is much lower...probably less than 0.1%.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote